bersanlimab (BI-505)

Antibody against ICAM-1, bersanlimab (BI505, BioInvent), was well-tolerated, but only showed limited clinical efficacy in MM patients. Most importantly, the CD38 x ICAM1 bispecific antibody demonstrated potent tumor inhibition activities in in-vivo myeloma and lymphoma models. These studies suggested that CD38 x ICAM-1 bispecific antibody has multiple modes of action for treating lymphoma and multiple myeloma.

Antibody against ICAM1, bersanlimab (BI505, BioInvent), was well-tolerated, but only showed limited clinical efficacy in MM patients. Most importantly, the CD38 x ICAM1 bispecific antibody showed complete tumor inhibition in a rituximab-resistant lymphoma PDX model, whereas daratumumab only showed minimal efficacy. In conclusion, the CD38 x ICAM1 bispecific antibody demonstrated improved efficacy and specificity toward CD38 + and ICAM1 + tumor cells and represents a novel approach for treating multiple myeloma and lymphoma.